Results 41 to 50 of about 15,262 (192)

Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay

Research and Practice in Thrombosis and Haemostasis, 2021
Background Thrombotic thrombocytopenic purpura (TTP) is a life‐threatening thrombotic microangiopathy (TMA) caused by a severe functional deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats‐13), the specific von ...
Nicolas Beranger, Sandrine Benghezal, Bérangère S. Joly, Sophie Capdenat, Adeline Delton, Alain Stepanian, Paul Coppo, Agnès Veyradier   +7 more
doaj   +1 more source

Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma [PDF]

, 2007
Reportedly, complexes between factor XI and ADAMTS13 are detected with a commercial ADAMTS13/FXI ELISA kit in plasma and are decreased in thrombotic thrombocytopenic purpura (TTP).
Anderson, Patricia J, Feys, Hendrik B, Gailani, David, Gao, Weiqiang, Majerus, Elaine M, Sadler, J. Evan, Vanhoorelbeke, Karen   +6 more
core   +2 more sources

Von Willebrand Factor and ADAMTS13 in COVID-19 and Beyond: A Question of Balance

European Medical Journal Nephrology, 2021
von Willebrand factor (VWF) is a large, adhesive, multimeric protein involved in haemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein. A deficiency or defect in VWF can lead to von Willebrand disease
Emmanuel J Favaloro, Brandon Michael Henry, Giuseppe Lippi   +2 more
doaj  

Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. [PDF]

, 2015
INTRODUCTION: Genetic and autoimmune risk factors contribute to the development of thrombotic thrombocytopenic purpura (TTP) but triggers are needed to bring about acute disease.
Brill, Brinkmann, Brinkmann, Bálint Mikes, Chapman, Chaturvedi, Chen, Clark, Clark, Derzsy, Dorottya Csuka, Falter, Fitzpatrick, Fuchs, Fujimura, Gombos, Gyula Domján, György Sinkovits, Hung, Ishikawa, Jagels, Judit Demeter, Karpman, Katalin Rázsó, Kessenbrock, Kremer Hovinga, Leffler, Marienn Réti, Massberg, Moatti-Cohen, Noris, Papayannopoulos, Peng, Peyvandi, Péter Farkas, Raife, Reti, Tsai, Urban, van Montfoort, Walters, Westwood1, Xu, Zoltán Prohászka, Ágota Schlammadinger   +44 more
core   +1 more source

ADAMTS13 inhibits H2O2-induced human venous endothelial cell injury to attenuate deep-vein thrombosis by blocking the p38/ERK signaling pathway

Chinese Journal of Physiology, 2023
Deep vein thrombosis (DVT) is a common complication in hematologic malignancies and immunologic disorders. Endothelial cell injury and dysfunction comprise the critical contributor for the development of DVT.
Guangfeng Zheng, Qiang Zhang, Chuanyong Li, Weijian Fan, Zhichang Pan, Yuting Zhou, Yan Chen, Jianjie Rong   +7 more
doaj   +1 more source

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura

Research and Practice in Thrombosis and Haemostasis, 2020
Background In immune‐mediated thrombotic thrombocytopenic purpura (iTTP), patients develop an immune response against the multidomain enzyme ADAMTS13.
Kadri Kangro, Elien Roose, An‐Sofie Schelpe, Edwige Tellier, Gilles Kaplanski, Jan Voorberg, Simon F. De Meyer, Andres Männik, Karen Vanhoorelbeke   +8 more
doaj   +1 more source

Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan

Frontiers in Medicine, 2022
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency (activity <10%).
Chun-Hui Lee, Chun-Hui Lee, Chun-Hui Lee, Yi-Ching Huang, Yi-Ching Huang, Sin-Syue Li, Sin-Syue Li, Ya-Ting Hsu, Ya-Ting Hsu, Ya-Ping Chen, Tsai-Yun Chen, Tsai-Yun Chen   +11 more
doaj   +1 more source

A case of refractory thrombotic thrombocytopenic purpura treated with plasmapheresis and rituximab [PDF]

, 2016
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder with no prevalence or incidence studies in sub-Saharan Africa. Acquired TTP has several causes, all of which lead to decreased activity of von Willebrand factor cleaving ...
Kirui, Nicholas, Sokwala, Ahmed
core   +4 more sources

Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura

Blood Advances, 2019
: Immune thrombotic thrombocytopenic purpura (iTTP) is primarily caused by immunoglobulin G (IgG)–type autoantibodies that bind and inhibit plasma ADAMTS13 activity and/or accelerate its clearance from circulation. Approximately 50% of patients with iTTP
Jingrui Sui, Wenjing Cao, Konstantine Halkidis, Mohammad S. Abdelgawwad, Nicole K. Kocher, Bryan Guillory, Lance A. Williams, Radhika Gangaraju, Marisa B. Marques, X. Long Zheng   +9 more
doaj   +1 more source

Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome [PDF]

, 2010
Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia.
Mastroianni Kirsztajn, Gianna, Polito, Maria Goretti   +1 more
core   +2 more sources